Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
OBSERVATIONAL
2013-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Epigenetics Based Diagnosis of Diabetes in Saliva and Blood Samples
NCT04011228
Gene Expression Profiling in Type 1 Diabetes
NCT00330954
Epigenetics of Muscle Insulin Resistance
NCT03259984
Metabolic Phenotypes and Heterogeneity in Disease Burden Risk in Type 1 Diabetes
NCT05609279
Genetics of Type 1 Diabetes in Chinese Adolescents and Youth
NCT01938365
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Phase I
Oral glucose tolerance test for Phase I
Oral glucose tolerance test for Diabetic patients in phase I
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oral glucose tolerance test for Phase I
Oral glucose tolerance test for Diabetic patients in phase I
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of Type I diabetes
* Willing to wear continuous blood glucose monitor as specified in protocol
Exclusion Criteria
Healthy control group Inclusion:
* 18-65 years old
* Willing to wear continuous blood glucose monitor as specified in protocol
Exclusion:
* Pregnant or planning to become pregnant during the study
* Diagnosis of Type I or II Diabetes
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Scripps Translational Science Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Eric Topol, MD
Director
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Scripps
San Diego, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
11-5649
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.